Killer cell lectin-like receptor subfamily K member 1 (NKG2D) receptor (NKG2D)

Killer cell lectin-like receptor subfamily K member 1 (NKG2D) is a potent activating receptor primarily expressed on natural killer (NK) cells, CD8+ T cells, and certain gamma-delta T cells [1, 2]. Encoded by the KLRK1 gene, it belongs to the C-type lectin-like receptor family and plays a critical role in immunosurveillance by recognizing stress-induced ligands like MICA, MICB, and ULBPs, which are typically absent from healthy tissues but upregulated during viral infection or malignant transformation [2, 3, 5]. Upon ligand binding, NKG2D recruits the DAP10 adapter protein to initiate signaling cascades that trigger cytokine production (e.g., IFN-gamma) and the direct cytotoxic destruction of target cells [1, 5]. In oncology, NKG2D is a major focus for immunotherapy, specifically in the development of chimeric antigen receptor (CAR) T and NK cell therapies that leverage the receptor's broad specificity for tumor-associated ligands [4, 9]. Conversely, in autoimmune and inflammatory diseases such as Crohn's disease and rheumatoid arthritis, the chronic over-activation of the NKG2D pathway contributes to pathological tissue damage, making it a target for antagonistic monoclonal antibodies [7, 8]. Key challenges in targeting NKG2D include managing cytokine release syndrome and overcoming the immune-suppressive effects of soluble ligands shed by tumors, which act as decoys to downregulate receptor expression [4, 6]. Sources: [1] UniProt (P26718: KLRK1_HUMAN). [2] Lanier, L. L. (2015). 'NKG2D Receptor and Its Ligands in Host Defense.' Cancer Immunology Research. [3] Nausch, N., & Cerwenka, A. (2008). 'NKG2D ligands in tumor immunity.' Oncogene. [4] Spear, P., et al. (2013). 'NKG2D ligands as therapeutic targets.' Cancer Immunity. [5] Raulet, D. H. (2003). 'Roles of the NKG2D immunoreceptor and its ligands.' Nature Reviews Immunology. [6] Waldhauer, I., & Steinle, A. (2008). 'NK cells and cancer immunosurveillance.' Oncogene. [7] Allez, M., et al. (2016). 'NKG2D blockade in Crohn's disease.' Gut. [8] ClinicalTrials.gov (NCT01203631: NNC0142-0002). [9] Celyad Oncology (Pipeline data on CYAD-01/02).

Other names

KLRK1CD314Natural killer group 2 member DKiller cell lectin-like receptor subfamily K member 1NKG2-D type II integral membrane protein

Targeted activation of immune effector cells through engineered receptor expression (CAR) or monoclonal antibody-mediated agonism to enhance anti-tumor immunity; antagonistic blockade of the receptor to inhibit pathological immune responses and tissue damage in chronic inflammatory and autoimmune conditions.